Cargando…
Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC
Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234848/ https://www.ncbi.nlm.nih.gov/pubmed/35770234 http://dx.doi.org/10.1177/11795549221103215 |
_version_ | 1784736169516335104 |
---|---|
author | Liu, Rong Zhou, Jianying Ling, Xia |
author_facet | Liu, Rong Zhou, Jianying Ling, Xia |
author_sort | Liu, Rong |
collection | PubMed |
description | Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop resistance to the treatment. Evidence from clinical studies suggests that treatment outcomes and resistance mechanisms vary depending on the choice of TKI therapy in the first-line setting. Hence, it is important to develop optimal treatment sequencing strategies that can provide maximum survival benefit for the patient. In this review we present clinical evidence in Asian patients with NSCLC for various EGFR TKIs, with the goal of supporting the optimization of treatment sequencing. |
format | Online Article Text |
id | pubmed-9234848 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-92348482022-06-28 Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC Liu, Rong Zhou, Jianying Ling, Xia Clin Med Insights Oncol Review Patients from Asia with non-small-cell lung cancer (NSCLC) often have mutations in the epidermal growth factor receptor (EGFR) gene. While an increasing number of EGFR tyrosine kinase inhibitors (TKIs) are now available for patients with EGFR mutation-positive NSCLC, most patients inevitably develop resistance to the treatment. Evidence from clinical studies suggests that treatment outcomes and resistance mechanisms vary depending on the choice of TKI therapy in the first-line setting. Hence, it is important to develop optimal treatment sequencing strategies that can provide maximum survival benefit for the patient. In this review we present clinical evidence in Asian patients with NSCLC for various EGFR TKIs, with the goal of supporting the optimization of treatment sequencing. SAGE Publications 2022-06-24 /pmc/articles/PMC9234848/ /pubmed/35770234 http://dx.doi.org/10.1177/11795549221103215 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Liu, Rong Zhou, Jianying Ling, Xia Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in Asian Patients With EGFR Mutation-Positive NSCLC |
title | Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in
Asian Patients With EGFR Mutation-Positive
NSCLC |
title_full | Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in
Asian Patients With EGFR Mutation-Positive
NSCLC |
title_fullStr | Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in
Asian Patients With EGFR Mutation-Positive
NSCLC |
title_full_unstemmed | Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in
Asian Patients With EGFR Mutation-Positive
NSCLC |
title_short | Optimizing Patient Outcomes Through Sequential EGFR TKI Treatment in
Asian Patients With EGFR Mutation-Positive
NSCLC |
title_sort | optimizing patient outcomes through sequential egfr tki treatment in
asian patients with egfr mutation-positive
nsclc |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234848/ https://www.ncbi.nlm.nih.gov/pubmed/35770234 http://dx.doi.org/10.1177/11795549221103215 |
work_keys_str_mv | AT liurong optimizingpatientoutcomesthroughsequentialegfrtkitreatmentinasianpatientswithegfrmutationpositivensclc AT zhoujianying optimizingpatientoutcomesthroughsequentialegfrtkitreatmentinasianpatientswithegfrmutationpositivensclc AT lingxia optimizingpatientoutcomesthroughsequentialegfrtkitreatmentinasianpatientswithegfrmutationpositivensclc |